Cowen Downgrades Fate Therapeutics (FATE) to Market Perform

Fate Therapeutics (FATE) collapses 55% after terminating Janssen deal, earns several downgrades

Shares of Fate Therapeutics (NASDAQ: FATE) are down more than 56% in pre-market after the company said it has declined a proposal from Janssen Biotech, which is owned by Johnson & Johnson (NYSE: JNJ), for the continuation of the collaboration and option agreement between the parties.

As a result, the agreement has been terminated and the FT596 product candidate is discontinued. Instead, the company plans to... More

BMO Capital Downgrades Fate Therapeutics (FATE) to Market Perform

BMO Capital analyst Etzer Darout downgraded Fate Therapeutics (NASDAQ: FATE) from Outperform to Market Perform with a price target of $7.00 (from $20.00).

For an analyst ratings summary and ratings history on Fate Therapeutics click here. For more ratings news on Fate Therapeutics click here.

Shares of Fate Therapeutics closed at $11.00 yesterday.

Truist Securities Downgrades Fate Therapeutics (FATE) to Hold

Truist Securities analyst Robyn Karnauskas downgraded Fate Therapeutics (NASDAQ: FATE) from Buy to Hold with a price target of $7.00 (from $46.00).

For an analyst ratings summary and ratings history on Fate Therapeutics click here. For more ratings news on Fate Therapeutics click here.

Shares of Fate Therapeutics closed at $11.00 yesterday.

Fate Therapeutics (FATE) PT Lowered to $8 at Morgan Stanley

Morgan Stanley analyst Michael Ulz lowered the price target on Fate Therapeutics (NASDAQ: FATE) to $8.00 (from $35.00) while maintaining a Equalweight rating.... More

Piper Sandler Downgrades Fate Therapeutics (FATE) to Neutral

(Updated - January 6, 2023 6:13 AM EST)

Piper Sandler analyst Edward Tenthoff downgraded Fate Therapeutics (NASDAQ: FATE) from Overweight to Neutral with a price target of $12.00 (from $71.00).

The analyst comments "Fate is discontinuing development of FT516, FT538 in AML, FT596 in B-Cell... More

Fate Therapeutics (FATE) PT Lowered to $5 at Baird

Baird analyst Jack Allen lowered the price target on Fate Therapeutics (NASDAQ: FATE) to $5.00 (from $28.00) while maintaining a Neutral rating.... More

Stifel Downgrades Fate Therapeutics (FATE ) to Hold

Stifel analyst Benjamin Burnett downgraded Fate Therapeutics (NASDAQ: FATE ) from Buy to Hold with a price target of $5.30 (from $107.00).

For an analyst ratings summary and ratings history on Fate Therapeutics click here. For more ratings news on Fate Therapeutics click here.

Shares of Fate Therapeutics closed at $11.00 yesterday.

After-hours movers: CytomX jumps on Moderna deal, WWE gains as McMahon supports possible sale

After-Hours Movers:

CytomX Therapeutics, Inc. (NASDAQ: CTMX) 52% HIGHER; The company and Moderna, Inc. (NASDAQ: MRNA) announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies utilizing Moderna's mRNA technologies and CytomX's Probody therapeutic platform.

Fate Therapeutics, Inc.... More

Fate Therapeutics (FATE) Announces Termination of Collaboration Agreement with Janssen

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, announced today that it has declined a proposal from Janssen Biotech, Inc. (Janssen) for continuation of the collaboration and option agreement between the parties on revised terms and conditions and, as a result, the agreement has been terminated and all collaboration activities will be wound down in the first quarter of 2023. In addition, the Company has completed a strategic review of its natural... More

Fate Therapeutics (FATE) Halted, News Pending

Fate Therapeutics (NASDAQ: FATE) Halted, News Pending

EF Hutton Starts Fate Therapeutics (FATE) at Buy

EF Hutton analyst Tony Butler initiates coverage on Fate Therapeutics (NASDAQ: FATE) with a Buy rating and a price target of $16.00.

For an analyst ratings summary and ratings history on Fate Therapeutics click here. For more ratings news on Fate Therapeutics click here.

Shares of Fate Therapeutics closed at $10.17 yesterday.